The inside story of how SalioGen, a startup trying to wrangle ‘jumping genes’ to make medicines, fell apart

Ryan Cross

Senior Science Correspondent

In the spring of 2022, Ray Tabibiazar summoned his scientists for a pep talk. His startup, SalioGen Therapeutics, had just raised $115 million for a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The inside story of how SalioGen, a startup trying to wrangle ‘jumping genes’ to make medicines, fell apart

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Exclusive: Vertex drops AAV gene therapy research, tRNA therapy partnership

Drugmakers exploit cancer’s ‘lethalities’ to make next class of targeted therapies, with first results for ...

Exclusive: After FDA firings, drug reviewers are asked to volunteer for administrative work

Feng Zhang’s protein nanoparticle startup Aera Therapeutics turns to lipid nanoparticles to jumpstart its pipeline

White House budget request would cut billions at NIH and CDC, add $500M for MAHA

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

The in­side sto­ry of how Sali­o­Gen, a start­up try­ing to wran­gle ‘jump­ing genes’ to make med­i­cines, fell apart

Senior Science Correspondent

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

The inside story of how SalioGen, a startup trying to wrangle ‘jumping genes’ to make medicines, fell apart